News - Depomed, Pharmaceutical

Filter

Current filters:

DepomedPharmaceutical

Popular Filters

PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal

22-10-2013

PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

Depomed expands geographic scope of metformin deal with Merck

10-09-2013

USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

US FDA grants priority review for Mallinckrodt's pain relief drug

29-07-2013

The US Food and Drug Administration has accepted and granted a priority review for the New Drug Application…

DepomedMallinckrodtNorth AmericaOxycodone and AcetaminophenPharmaceuticalRegulation

Briefs: Depomed drops Sefelsa after CRL: Sun Pharma stalking Meda?

03-06-2013

US specialty drugmaker Depomed (Nasdaq: DEPO) says that Food and Drug Administration issued a complete…

DepomedMedaMergers & AcquisitionsMetabolicsNorth AmericaPharmaceuticalRegulationResearchSefelsaSun Pharmaceutical Industries

Views on US physician prescribing and payer reimbursement across multiple neuropathic pain populations

29-05-2013

Expanded labeling for additional neuropathic pain (NP) populations and/or broader NP labeling (peripheral…

DepomedGraliseHorizantJanssenMarkets & MarketingNeurologicalNorth AmericaNucyntaPharmaceuticalXenoPort

FDA should not approve paroxetine or gabapentin for hot flashes, says Public Citizen

05-03-2013

A drug approved to treat depression and other mental health disorders and another designed to prevent…

DepomedgabapentinHisamitsu PharmaNorth AmericaparoxetinePharmaceuticalRegulationWomen's Health

Depomed says BREEZE 3 data for Serada shows benefits for hot flashes

04-10-2012

USA-based Depomed (Nasdaq: DEPO) is presenting two abstracts from its Phase III clinical trial, BREEZE…

DepomedMetabolicsPharmaceuticalResearchSeradaWomen's Health

Depomed sues FDA over orphan status exclusivity for Gralise

26-09-2012

US drugmaker Depomed (Nasdaq: DEPO) says it has filed an action in federal district court for the District…

DepomedGraliseLegalNeurologicalNorth AmericaPharmaceuticalRare diseases

Depomed to file NDA for Serada; with Valeant sues Watson over Glumetza

20-04-2012

US drugmaker Depomed (Nasdaq: DEPO) says that it has completed a Type B pre-New Drug Application meeting…

DepomedDiabetesGenericsGlumetzaNorth AmericaPatentsPharmaceuticalRegulationResearchSeradaValeant PharmaceuticalsWatson PharmaceuticalsWomen's Health

Tapentadol ER has advantages over Lyrica in reducing diabetic neuropathy pain intensity

21-03-2012

Surveyed US neurologists and managed care organization (MCO) pharmacy directors agree that reducing pain…

DepomedGraliseJohnson & JohnsonLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticaltapentadol

Depomed files patent infringement suits relating to Gralise

05-03-2012

California, USA-based Depomed (Nasdaq: DEPO) yesterday filed a patent infringement law suit in the US…

ActavisDepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

Depomed shares plummet as Ph III Serada trial fails one endpoint

17-10-2011

Shares of US specialty drugmaker Depomed (Nasdaq: DEPO) fell 28.2% to $4.52 last Friday, after the company…

DepomedgabapentinNeurologicalPharmaceuticalResearchSerada

Santarus and Depomed expand US deal on Glumetza

23-08-2011

US drugmakers Santarus (Nasdaq: SNTS) and Depomed (Nasdaq: DEPO) have entered into a new commercialization…

DepomedDiabetesGlumetzaLicensingNorth AmericaPharmaceuticalSantarus

Back to top